Trial Profile
A study of cabazitaxel treatment in castration resistant bone metastatic prostate cancer patients evaluating the tumor microenvironment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms CABA-BONE
- 06 Feb 2020 Status changed from recruiting to completed.
- 23 Jan 2020 This trial has been completed in Greece, according to European Clinical Trials Database record.
- 10 May 2019 Planned End Date changed from 1 Jul 2019 to 1 Sep 2020.